Cargando…
Difference-in-Differences Method in Comparative Effectiveness Research: Utility with Unbalanced Groups
BACKGROUND: Comparative effectiveness research (CER) often includes observational studies utilizing administrative data. Multiple conditioning methods can be used for CER to adjust for group differences, including difference-in-differences (DiD) estimation. OBJECTIVE: This study presents DiD and dem...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937082/ https://www.ncbi.nlm.nih.gov/pubmed/27371369 http://dx.doi.org/10.1007/s40258-016-0249-y |
_version_ | 1782441648115941376 |
---|---|
author | Zhou, Huanxue Taber, Christopher Arcona, Steve Li, Yunfeng |
author_facet | Zhou, Huanxue Taber, Christopher Arcona, Steve Li, Yunfeng |
author_sort | Zhou, Huanxue |
collection | PubMed |
description | BACKGROUND: Comparative effectiveness research (CER) often includes observational studies utilizing administrative data. Multiple conditioning methods can be used for CER to adjust for group differences, including difference-in-differences (DiD) estimation. OBJECTIVE: This study presents DiD and demonstrates how to apply this conditioning method to estimate treatment outcomes in the CER setting by utilizing the MarketScan® Databases for multiple sclerosis (MS) patients receiving different therapies. METHODS: The sample included 6762 patients, with 363 in the Test Cohort [glatiramer acetate (GA) switched to fingolimod (FTY)] and 6399 in the Control Cohort (GA only, no switch) from a US administrative claims database. A trend analysis was conducted to rule out concerns regarding regression to the mean and to compare relapse rates among treatment cohorts. DiD analysis was used to enable comparisons among the Test and Control Cohorts. Logistic regression was used to estimate the probability of relapse after switching from GA to FTY, and to compare group differences in the pre- and post-index periods. RESULTS: Crude DiD analysis showed that in the pre-index period more patients in the Test Cohort experienced an MS relapse and had a higher mean number of relapses than in the Control Cohort. During the pre-index period, numeric and relative data for MS relapses in patients in the Test Cohort were significantly higher than in the Control Cohort, while no significant between-group differences emerged during the post-index period. Generalized linear modeling with DiD regression estimation showed that the mean number of MS relapses decreased significantly in the post-index period among patients in the Test Cohort compared with patients in the Control Cohort. CONCLUSION: In this study, an MS population was utilized to demonstrate how DiD can be applied to estimate treatment effects in a heterogeneous population, where the Test and Control Cohorts varied greatly. The results show that DiD offers a robust method for comparing diverse cohorts when other risk-adjustment methods may not be adequate. |
format | Online Article Text |
id | pubmed-4937082 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-49370822016-07-19 Difference-in-Differences Method in Comparative Effectiveness Research: Utility with Unbalanced Groups Zhou, Huanxue Taber, Christopher Arcona, Steve Li, Yunfeng Appl Health Econ Health Policy Original Research Article BACKGROUND: Comparative effectiveness research (CER) often includes observational studies utilizing administrative data. Multiple conditioning methods can be used for CER to adjust for group differences, including difference-in-differences (DiD) estimation. OBJECTIVE: This study presents DiD and demonstrates how to apply this conditioning method to estimate treatment outcomes in the CER setting by utilizing the MarketScan® Databases for multiple sclerosis (MS) patients receiving different therapies. METHODS: The sample included 6762 patients, with 363 in the Test Cohort [glatiramer acetate (GA) switched to fingolimod (FTY)] and 6399 in the Control Cohort (GA only, no switch) from a US administrative claims database. A trend analysis was conducted to rule out concerns regarding regression to the mean and to compare relapse rates among treatment cohorts. DiD analysis was used to enable comparisons among the Test and Control Cohorts. Logistic regression was used to estimate the probability of relapse after switching from GA to FTY, and to compare group differences in the pre- and post-index periods. RESULTS: Crude DiD analysis showed that in the pre-index period more patients in the Test Cohort experienced an MS relapse and had a higher mean number of relapses than in the Control Cohort. During the pre-index period, numeric and relative data for MS relapses in patients in the Test Cohort were significantly higher than in the Control Cohort, while no significant between-group differences emerged during the post-index period. Generalized linear modeling with DiD regression estimation showed that the mean number of MS relapses decreased significantly in the post-index period among patients in the Test Cohort compared with patients in the Control Cohort. CONCLUSION: In this study, an MS population was utilized to demonstrate how DiD can be applied to estimate treatment effects in a heterogeneous population, where the Test and Control Cohorts varied greatly. The results show that DiD offers a robust method for comparing diverse cohorts when other risk-adjustment methods may not be adequate. Springer International Publishing 2016-07-01 2016 /pmc/articles/PMC4937082/ /pubmed/27371369 http://dx.doi.org/10.1007/s40258-016-0249-y Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Research Article Zhou, Huanxue Taber, Christopher Arcona, Steve Li, Yunfeng Difference-in-Differences Method in Comparative Effectiveness Research: Utility with Unbalanced Groups |
title | Difference-in-Differences Method in Comparative Effectiveness Research: Utility with Unbalanced Groups |
title_full | Difference-in-Differences Method in Comparative Effectiveness Research: Utility with Unbalanced Groups |
title_fullStr | Difference-in-Differences Method in Comparative Effectiveness Research: Utility with Unbalanced Groups |
title_full_unstemmed | Difference-in-Differences Method in Comparative Effectiveness Research: Utility with Unbalanced Groups |
title_short | Difference-in-Differences Method in Comparative Effectiveness Research: Utility with Unbalanced Groups |
title_sort | difference-in-differences method in comparative effectiveness research: utility with unbalanced groups |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937082/ https://www.ncbi.nlm.nih.gov/pubmed/27371369 http://dx.doi.org/10.1007/s40258-016-0249-y |
work_keys_str_mv | AT zhouhuanxue differenceindifferencesmethodincomparativeeffectivenessresearchutilitywithunbalancedgroups AT taberchristopher differenceindifferencesmethodincomparativeeffectivenessresearchutilitywithunbalancedgroups AT arconasteve differenceindifferencesmethodincomparativeeffectivenessresearchutilitywithunbalancedgroups AT liyunfeng differenceindifferencesmethodincomparativeeffectivenessresearchutilitywithunbalancedgroups |